Home » FDA Clears Novartis Combination Therapy for Anaplastic Thyroid Cancer
FDA Clears Novartis Combination Therapy for Anaplastic Thyroid Cancer
Drugs Submissions and Approvals
The FDA approved Novartis’ combination therapy for anaplastic thyroid cancer that cannot be removed surgically.
The therapy uses a combination of the company’s Mekinist and Tafinlar. It is the first FDA-approved treatment for patients with such a form of cancer and the third for patients with this specific gene mutation.
The combination is also approved for use in a type of lung cancer with the BRAF V600E gene.